IMV Inc. has announced its financial results for 2020, highlighting significant progress in its immunotherapy pipeline, especially Maveropepimut-S. With cash reserves of $46.4 million, the company aims to advance its clinical programs, including two Phase 2 trials and exploratory studies in multiple solid tumors. IMV reported a net loss of $34.9 million, attributed to increased research and administrative expenses. The company is poised for 2021 with multiple milestones, including FDA engagement and new clinical trials for its promising DPX-based therapies.
IMV Inc. will hold a conference call and webcast on March 17, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. Participants can join by calling (866) 211-3204 (U.S. & Canada) or (647) 689-6600 (international) with conference ID: 8998652. The webcast will also be accessible live via the company’s website. IMV is focused on advancing immunotherapy, particularly its lead candidate, DPX-Survivac, for ovarian cancer, along with a COVID-19 vaccine development.
IMV announced its executive management team's participation in the H.C. Wainwright Global Life Sciences Conference, taking place virtually on March 9-10, 2021. The presentation is scheduled for March 9 at 7:00 AM ET and will be available for 30 days on IMV’s website. The company is pioneering cancer immunotherapies and vaccines, with a focus on its lead candidate, DPX-Survivac, which targets survivin. IMV highlights potential FDA accelerated approval and the ongoing clinical studies for its therapies.
IMV, a clinical-stage biopharmaceutical company, announced participation in two virtual investor events. The BTIG Fireside Chat is scheduled for January 7, 2021, at 12:15 PM ET. The H.C. Wainwright Fireside Chat (Bioconnect 2021 Conference) will occur on January 11, 2021, starting at 6:00 AM ET and will be available on demand for a week. Webcasts of these events can be found in the investors section of IMV’s website. The press release notes that forward-looking statements are made regarding FDA approvals and ongoing trials with the potential for varied outcomes.
IMV Inc. (Nasdaq: IMV) announced an update on its DPX-COVID-19 vaccine candidate aimed at preventing COVID-19. The company has completed safety studies confirming a favorable profile and long-lasting antibody response. Preliminary results show promise for protection against SARS-CoV-2 variants, as targeted areas of the vaccine are less prone to mutations. IMV received Cdn $10M in non-dilutive funding and is collaborating with manufacturing partners to produce hundreds of millions of doses globally. Further preclinical studies and updates are expected in Q1 2021.